Terence Z. Wong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Terence Z. Wong has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Anthony S. Zannas
A Psychiatry and Behavioral Sciences , Duke University Medical Center , Durham , NC , USA
1 shared publicationColm B. Kelleher
Department of Radiology, Division of Nuclear Medicine and Radiotheranostics, Duke University Medical Center, Box 3949, Durham, NC 27710
1 shared publication- Heiko Schöder
Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY
1 shared publication Hemant Desai
Department of Radiology, Duke University Medical Center, Durham, NC, 27710, USA
1 shared publicationHumberto G. Mendoza
Memorial Sloan Kettering Cancer Center
1 shared publication- James R. Burke
Duke University Medical Center
1 shared publication
Latest Publications
- 27 March 2025
- Published by Springer Nature
- p. 87-110
Hepatic Arterial Infusion Pumps for Malignancy From a Molecular Imaging and Therapy Perspective
- 27 March 2025
- Published by Springer Nature
- p. 87-110
Hepatic Arterial Infusion Pumps for Malignancy From a Molecular Imaging and Therapy Perspective
- 1 December 2022
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 219 (6) , 880-881
IV Contrast Material for PET/CT: Point—Putting the CT Into PET/CT
This article does not include an Please see the accompanying Counterpoint by Merissa N. Zeman and Esma A. Akin.
- 1 December 2022
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 219 (6) , 880-881
IV Contrast Material for PET/CT: Point—Putting the CT Into PET/CT
This article does not include an Please see the accompanying Counterpoint by Merissa N. Zeman and Esma A. Akin.
- 29 August 2019
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 20 (10) , 78
Molecular Imaging and Therapy for Neuroendocrine Tumors
Neuroendocrine tumors (NETs) are relatively rare, with 12,000–15,000 new cases diagnosed annually in the USA. Although NETs are a diverse group of neoplasms, they share common molecular targets that can be exploited using nuclear medicine techniques for both imaging and therapy. NETs have traditionally been imaged with SPECT imaging using 111In-labeled octreotide analogs to detect neoplasms with somatostatin receptors. In addition, certain NETs (pheochromocytomas, paragangliomas, and neuroblastomas) are also effectively imaged using 123I- or 131I-labeled metaiodobenzylguanidine (MIBG), an analog of guanethidine. More recently, PET imaging with 68Ga-labeled somatostatin receptor (SSR) analogs allows neuroendocrine tumors to be imaged with much higher sensitivity. 68Ga-DOTATATE was approved as a PET tracer by the FDA in June 2016. In addition to imaging, both MIBG and DOTATATE can be labeled with therapeutic radionuclides to deliver targeted radiation selectively to macroscopic and microscopic tumor sites. The incorporation of the same molecular probe for imaging and therapy provides a radio-theranostic approach to identifying, targeting, and treating tumors. Over the years, several centers have experience treating NETs with high-dose 131I-MIBG. 177Lu-DOTATATE was approved by the FDA in 2018 for treatment of gastroenteropancreatic NETs and constitutes a major advancement in the treatment of these diseases. In this paper, we provide an overview of imaging and treating neuroendocrine tumors using MIBG and SSR probes. Although uncommon, neuroendocrine tumors have provided the largest experience for targeted radionuclide imaging and therapy (with the exception of radioiodine treatment for thyroid disease). In addition to benefitting patients with these rare tumors, the knowledge gained provides a blueprint for the development of future paired diagnostic/therapeutic probes for treating other diseases, such as prostate cancer.
- 29 August 2019
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 20 (10) , 78
Molecular Imaging and Therapy for Neuroendocrine Tumors
Neuroendocrine tumors (NETs) are relatively rare, with 12,000–15,000 new cases diagnosed annually in the USA. Although NETs are a diverse group of neoplasms, they share common molecular targets that can be exploited using nuclear medicine techniques for both imaging and therapy. NETs have traditionally been imaged with SPECT imaging using 111In-labeled octreotide analogs to detect neoplasms with somatostatin receptors. In addition, certain NETs (pheochromocytomas, paragangliomas, and neuroblastomas) are also effectively imaged using 123I- or 131I-labeled metaiodobenzylguanidine (MIBG), an analog of guanethidine. More recently, PET imaging with 68Ga-labeled somatostatin receptor (SSR) analogs allows neuroendocrine tumors to be imaged with much higher sensitivity. 68Ga-DOTATATE was approved as a PET tracer by the FDA in June 2016. In addition to imaging, both MIBG and DOTATATE can be labeled with therapeutic radionuclides to deliver targeted radiation selectively to macroscopic and microscopic tumor sites. The incorporation of the same molecular probe for imaging and therapy provides a radio-theranostic approach to identifying, targeting, and treating tumors. Over the years, several centers have experience treating NETs with high-dose 131I-MIBG. 177Lu-DOTATATE was approved by the FDA in 2018 for treatment of gastroenteropancreatic NETs and constitutes a major advancement in the treatment of these diseases. In this paper, we provide an overview of imaging and treating neuroendocrine tumors using MIBG and SSR probes. Although uncommon, neuroendocrine tumors have provided the largest experience for targeted radionuclide imaging and therapy (with the exception of radioiodine treatment for thyroid disease). In addition to benefitting patients with these rare tumors, the knowledge gained provides a blueprint for the development of future paired diagnostic/therapeutic probes for treating other diseases, such as prostate cancer.
- 3 April 2013
- Published by Taylor & Francis in Neurocase
- Vol. 20 (4) , 466-473
Impact of18F-florbetapir PET imaging of β-amyloid neuritic plaque density on clinical decision-making
18F-florbetapir positron emission tomography (PET) imaging of the brain is now approved by the Food and Drug Administration (FDA) approved for estimation of β-amyloid neuritic plaque density when evaluating patients with cognitive impairment. However, its impact on clinical decision-making is not known. We present 11 cases (age range 67–84) of cognitively impaired subjects in whom clinician surveys were done before and after PET scanning to document the theoretical impact of amyloid imaging on the diagnosis and treatment plan of cognitively impaired subjects. Subjects have been clinically followed for about 5 months after the PET scan. Negative scans occurred in five cases, leading to a change in diagnosis for four patients and a change in treatment plan for two of these cases. Positive scans occurred in six cases, leading to a change in diagnosis for four patients and a change in treatment plan for three of these cases. Following the scan, only one case had indeterminate diagnosis. Our series suggests that both positive and negative florbetapir PET scans may enhance diagnostic certainty and impact clinical decision-making. Controlled longitudinal studies are needed to confirm our data and determine best practices.
- 3 April 2013
- Published by Taylor & Francis in Neurocase
- Vol. 20 (4) , 466-473
Impact of18F-florbetapir PET imaging of β-amyloid neuritic plaque density on clinical decision-making
18F-florbetapir positron emission tomography (PET) imaging of the brain is now approved by the Food and Drug Administration (FDA) approved for estimation of β-amyloid neuritic plaque density when evaluating patients with cognitive impairment. However, its impact on clinical decision-making is not known. We present 11 cases (age range 67–84) of cognitively impaired subjects in whom clinician surveys were done before and after PET scanning to document the theoretical impact of amyloid imaging on the diagnosis and treatment plan of cognitively impaired subjects. Subjects have been clinically followed for about 5 months after the PET scan. Negative scans occurred in five cases, leading to a change in diagnosis for four patients and a change in treatment plan for two of these cases. Positive scans occurred in six cases, leading to a change in diagnosis for four patients and a change in treatment plan for three of these cases. Following the scan, only one case had indeterminate diagnosis. Our series suggests that both positive and negative florbetapir PET scans may enhance diagnostic certainty and impact clinical decision-making. Controlled longitudinal studies are needed to confirm our data and determine best practices.
- Top Cited Papers
- 1 August 2010
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 195 (2) , 310-320
A Systematic Review of the Factors Affecting Accuracy of SUV Measurements
OBJECTIVE. There is growing interest in using PET/CT for evaluating early response to therapy in cancer treatment. Although widely available and convenient to use, standardized uptake value (SUV) measurements can be influenced by a variety of biologic and technologic factors. Many of these factors can be addressed with close attention to detail and appropriate quality control. This article will review factors potentially affecting SUV measurements and provide recommendations on ways to minimize when using serial PET to assess early response to therapy.CONCLUSION. Scanner and reconstruction parameters can significantly affect SUV measurements. When using serial SUV measurements to assess early response to therapy, imaging should be performed on the same scanner using the same image acquisition and reconstruction protocols. In addition, attention to detail is required for accurate determination of the administered radiopharmaceutical dose.
- 1 August 2010
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 195 (2) , 310-320
Top Cited PapersA Systematic Review of the Factors Affecting Accuracy of SUV Measurements
OBJECTIVE. There is growing interest in using PET/CT for evaluating early response to therapy in cancer treatment. Although widely available and convenient to use, standardized uptake value (SUV) measurements can be influenced by a variety of biologic and technologic factors. Many of these factors can be addressed with close attention to detail and appropriate quality control. This article will review factors potentially affecting SUV measurements and provide recommendations on ways to minimize when using serial PET to assess early response to therapy.CONCLUSION. Scanner and reconstruction parameters can significantly affect SUV measurements. When using serial SUV measurements to assess early response to therapy, imaging should be performed on the same scanner using the same image acquisition and reconstruction protocols. In addition, attention to detail is required for accurate determination of the administered radiopharmaceutical dose.